INTRODUCTION Beta-lactam/beta-lactamase inhibitor combination antimicrobials (BLBLIs)
are among the most controversial classes of antibiotic agents available for the treatment of …

Objectives Extended-spectrum β-lactamases (ESBLs) present a serious challenge in the
treatment of Gram-negative bacterial infections. ESBLs mediate resistance to most β …

Therapy of infections caused by extended‐spectrum β‐lactamase (ESBL)‐producing
bacteria with an antimicrobial to which they are resistant results in treatment failure, higher …

Infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria are
associated with worse outcomes and have limited treatment options. Carbapenems remain …

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)–
producing pathogens is recognized globally as one of the most pressing concerns facing the …

Background extended spectrum β-lactamase (ESBL) producing gram negative bacilli are
becoming a growing problem worldwide with difficulties in designing a national formulary for …

Introduction: Extended spectrum β-lactamases (ESBL) and AmpC β-lactamases are
increasing causes of resistance in many Gram-negative pathogens of common infections …

Introduction: The spread of extended-spectrum β–lactamase (ESBL)-producing
Enterobacteriaceae has become a major public health threat worldwide. Area covered: A …

Infections due to multidrug-resistant gram-negative bacteria are rapidly increasing in both
health care and community settings. In particular, extended-spectrum β-lactamase (ESBL) …

In this issue a provocative study authored by Jesús Rodrıguez Bano and colleagues asserts
that the b-lactam/b-lactamase inhibitor (BLBLI) combinations piperacillin/tazobactam and …